Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Katerina Kubackova"'
Autor:
Veronika Vymetalkova, Pavel Soucek, Tereza Kunicka, Katerina Jiraskova, Veronika Brynychova, Barbara Pardini, Vendula Novosadova, Zdena Polivkova, Katerina Kubackova, Renata Kozevnikovova, Miloslav Ambrus, Ludmila Vodickova, Alessio Naccarati, Pavel Vodicka
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0134463 (2015)
Variations in the TP53 gene have been suggested to play a role in many cancers, including breast. We previously observed an association between TP53 haplotypes based on four polymorphisms (rs17878362, rs1042522, rs12947788, and rs17884306) and the ri
Externí odkaz:
https://doaj.org/article/daa9818343444ee98abf92c5511e42d0
Autor:
Štěpán Tuček, Pavel Janíček, Dagmar Adámková Krákorová, Katerina Kubackova, Jana Prausová, Iva Staniczková Zambo, Ladislav Dušek, Tomáš Tomáš, Igor Kiss
Publikováno v:
Pathology & Oncology Research. 24:623-630
Ewing sarcoma (ES) is an exceptionally rare tumor in adults. Data regarding outcomes of adult patients with ES and experiences with age-adapted therapeutic strategies are very limited. The aim of this study was to evaluate prognostic factors and clin
Autor:
Tomas Buchler, Tomáš Pavlík, Milada Zemanova, Ondrej Slaby, Rostislav Vyzula, Ladislav Dušek, Bohuslav Melichar, Ondrej Fiala, Katerina Kubackova, Veronika Veskrnova, Marek Svoboda, Alexandr Poprach, Michaela Honzirkova, Zbynek Bortlicek
Publikováno v:
European Urology. 70:469-475
Background It is currently not known whether treatment with anti–vascular endothelial growth factor agents for metastatic renal cell carcinoma (mRCC) can be safely discontinued in patients achieving a complete response (CR). Objective To assess out
Autor:
Igor Kiss, Milada Zemanova, Ondrej Fiala, Zbynek Bortlicek, Rostislav Vyzula, Tomas Buchler, Katerina Kubackova, Alexandr Poprach, Bohuslav Melichar, Ladislav Dušek
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 32:569-575
Objectives: The aim of the present study was to describe the efficacy and safety of everolimus in the treatment of metastatic renal cell carcinoma (mRCC) after administration of 1 vs. 2 prior tyrosine kinase inhibitors (TKIs). Patients and methods: A
Autor:
Bohuslav Melichar, Marek Svoboda, Jana Hornova, Zbyněk Bortlíček, Alexandr Poprach, Tomas Buchler, Tomáš Pavlík, Ondřej Slabý, Rostislav Vyzula, Milada Zemanova, Katerina Kubackova, Ladislav Dušek, Igor Kiss, Hana Študentová, Ondrej Fiala, Radek Lakomý
Publikováno v:
Drugsaging. 33(9)
Background Although a significant proportion of patients with metastatic renal cell carcinoma (mRCC) are elderly, the data on the outcomes of targeted therapies in this population are limited. The aim of the present retrospective registry-based study
Autor:
Katerina, Kubackova, Bohuslav, Melichar, Zbynek, Bortlicek, Tomas, Pavlik, Alexandr, Poprach, Marek, Svoboda, Radek, Lakomy, Rostislav, Vyzula, Igor, Kiss, Ladislav, Dusek, Jana, Prausova, Tomas, Buchler, Petr, Cinek
Publikováno v:
Targeted oncology. 10(4)
The study aimed to compare two prognostic models in terms of progression-free survival (PFS), median overall survival (OS), and 1-year survival in patients treated first-line with sunitinib for metastatic renal cell carcinoma (mRCC). Data from patien
Autor:
Tereza Kunická, Pavel Soucek, Ludmila Vodickova, Pavel Vodicka, Zdena Polivkova, Veronika Vymetalkova, Miloslav Ambrus, Veronika Brynychova, Katerina Kubackova, Vendula Novosadova, Renata Kozevnikovova, Alessio Naccarati, Katerina Jiraskova, Barbara Pardini
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0134463 (2015)
PLoS ONE
PLoS ONE
Variations in the TP53 gene have been suggested to play a role in many cancers, including breast. We previously observed an association between TP53 haplotypes based on four polymorphisms (rs17878362, rs1042522, rs12947788, and rs17884306) and the ri
Autor:
Radek Lakomy, Ladislav Dušek, Igor Kiss, Zbynek Bortlicek, Ondrej Fiala, Rostislav Vyzula, Tomas Buchler, Tomáš Pavlík, Oldrich Coufal, Marek Svoboda, Milada Zemanova, Bohuslav Melichar, Alexandr Poprach, Katerina Kubackova
Publikováno v:
European journal of cancer (Oxford, England : 1990). 51(4)
Aim: The aim of this retrospective, registry-based study was to analyse treatment outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib and renal insufficiency (RI). Methods: The cohort included 790 patients treated
Autor:
M. Kovar, Katerina Kubackova, L. Rozprimova, O. Hovorka, Tomas Mrkvan, M Sírová, Vladimir Subr, Jiří Strohalm, Karel Ulbrich, Blanka Rihova
Publikováno v:
Scopus-Elsevier
Conjugates based on N-(2-hydroxypropyl)methacrylamide (HPMA) represent a new generation of antibody-targeted polymeric anticancer drugs with both cytotoxic and immunoprotecting/immunomobilizing activity. 20-90% of mice that are cured of EL4 mouse T-c
Autor:
Tomas Buchler, Tomáš Pavlík, Katerina Kubackova, Rostislav Vyzula, Zdenek Linke, Bohuslav Melichar, Jana Prausová, Z. Bortlicek, Petra Pokorná
Publikováno v:
Targeted oncology. 10(3)
The aim of this study was to describe the characteristics and outcomes of a large cohort of patients treated with sorafenib in clinical practice and to identify predictive factors associated with prognosis. Patient data were obtained from the nationa